The purpose of this study is to evaluate the effects of HQK-1001 on Hb F in subjects with
sickle cell disease.
We will connect you to the doctor responsible for this trial and help you get more information.
Locations near you
Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Full eligibility criteria for NCT01601340
Ages eligible for Study
12 Years to 60 Years
Genders eligible for Study
Accepts Healthy Volunteers
Males and females between 12 and 60 years of age
Diagnosis of SCD, type Hb SS or Hb S-B0 Thalassemia
At least 1 episode of SCD pain crisis, acute chest syndrome, other acute SCD complications, or leg ulcers in the 12 months prior to screening
Not being treated with Hydroxyurea (HU); if HU treatment has been previously administered and then discontinued, at least 3 months must have elapsed since last dose of HU
If subject has been transfused in the 3 months prior to screening, then Hb A level < 20% at screening
Baseline Hb F level obtained within 14 days prior to randomization
Able to swallow tablets
Able and willing to give informed consent and/or assent
If subject is a woman of child-bearing potential (WCBP), she must have a negative serum pregnancy test within 14 days of first dose of HQK-1001 and a negative urine pregnancy test prior to dosing on Day 1
If a subject is a WCBP, she must agree to use an effective form of contraception starting at screening and for one month after HQK-1001 discontinuation
Sexually active male subjects who have not had a vasectomy must agree to use latex condoms with WCBP partners or ensure that their partner(s) use an effective form of contraception starting at screening and for one month after HQK-1001 discontinuation.
Assigned to a regular transfusion program
Use of erythropoiesis stimulating agents within 90 days prior to screening
An SCD pain crisis or SCD-related acute complication within 3 weeks prior to randomization
More than 5 SCD pain crisis or SCD-related acute complications within 12 months prior to screening
Pulmonary hypertension requiring therapy
ALT or AST > 3x ULN
Serum creatinine > 1.5x ULN
Serum amylase levels > 1.5x ULN
Serum lipase level > 1.5x ULN
A serious, concurrent illness that would limit ability to complete or comply with the study requirements
An acute illness (e.g., febrile, GI, respiratory) within 72 hours prior to screening
History of syncope, clinically significant dysrhythmias or resuscitation from sudden death due to SCD-related complication
Symptomatic peptic ulcer, hiatus hernia, or gastroesophageal reflux disease (GERD)
History of pancreatitis
Chronic opiate use, which, in the view of the investigator, could confound evaluation of an investigational drug
Current abuse of alcohol or drugs
Use of another investigational agent within 4 weeks or 5 half-lives, whichever is longer, prior to screening
Currently pregnant or breast feeding a child
Known infection with HIV-1
Infection with hepatitis B or hepatitis C, such that subjects are currently on anti-viral therapy or will be placed on therapy
All locations for NCT01601340
United States (11)
University of South Alabama
Mobile, Alabama, United States, 36617-2238
Children's Hospital and Research Center - Oakland
Oakland, California, United States, 94609
Children's National Hospital
Washington, District of Columbia, United States, 20010
Howard University Hospital
Washington, District of Columbia, United States, 20060
Georgia Health Sciences University
Augusta, Georgia, United States, 30912
University of Illinois at Chicago
Chicago, Illinois, United States, 60612
Tufts Medical Center
Boston, Massachusetts, United States, 02111
The Children's Hospital at Montefiore Medical Center
Bronx, New York, United States, 10467
New York Methodist Hospital
Brooklyn, New York, United States, 11215
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States, 27599
Virginia Commonwealth Univeristy - Center on Health Disparities
Richmond, Virginia, United States, 23298
University Health Network Toronto General Hospital
Toronto, Ontario, Canada, M5G2C4
Abu El Reesh Pediatric University Hospital
Ain Sham University Hospital
University of the West Indies
Mona, Kingston 7, Jamaica
American University of Beirut Medical Center
Chronic Care Center
Rafik Hariri University Hospital
View full eligibility
Tris trial is registered with FDA with number: NCT01601340. The sponsor of the trial is HemaQuest Pharmaceuticals Inc. and it is looking for 77 volunteers for the current phase.
Official trial title: A Randomized, Placebo-controlled, Phase 2 Study of HQK-1001 in Sickle Cell Disease
1What's a trial
4Get in touch
What's a trial
Not sure you're well informed about clinical trials? Learn more about their benefits, risks and other important details.
Enter your details like condition, age, gender and other preferences and we will show you a list of all relevant clinical trials.
Review the summary of the selected clinical trial and all the locations near you in order to see if it's of interest to you.
Get in touch
You've found an interesting trial? We'll need a bit more information about you so we can connect you to the doctor in charge.
Thank you for applying!
We'll contact you soon with more information.
Consult your doctor?
Some people want to consult their doctor before considering participation in a clinical trial. This is absolutely normal as your doctor should know your medical history and should be able to advise you. If you want you can easily share the information for this trial with your doctor by clicking on the button below.